To evaluate the patterns of recurrence and its value in target delineation for postoperative radiotherapy(PORT) in patients with stage III thoracic esophageal squmous cell carcinoma(ESCC) after esophagectomy.
Results:
The overall failure rates was 75.7%(299/395). Locoregional recurrence(LR) was found in 48.4% of patients, distant metastasis(DM) in 16.2%, and LR plus DM in 4.3%; the total rate of LR and DM were 52.7% and 20.5%, respectively. There were 208 patients recurred with LR, 26.9%(56) recurred in supraclavicular/neck(51 in supraclavicular), 69.7% (145) in mediastinum, and 19.7% (41) in upper abdomen (38 in para-aortic lymph node). 92.8% of LR involved locoregional lymph nodes; the rate of anastomotic recurrence was 5.1% (20/395). Further analysis showed that upper-mediastinal recurrence accounted for 88.7% of mediastinal recurrence. The estimated 1-, 3-, and 5-year accumulated LR rates for all patients were 32.2%, 55.1% and 60.1%. Multivariate COX and logistic regression analysis showed that TNM stage and adjuvant therapy were independent factor for LR (p<0.05); PORT could reduce LR, especially in patients with middlethoracic segment, IIIA and IIIB disease, two-field esophagectomy, less than 6 dissected lymph node or severe adhesion at surgery (p<0.05); but POCT did not decrease LR.
Conclusion:
The recurrence rate was very high in stage III thoracic ESCC patients, LR was the main pattern of failure; TNM stage was one of the most important factor for LR. PORT could reduce LR but POCT could not. Upper-mediastinum was the most common site of recurrence, followed by supraclavicular and para-aortic regions; these areas should be consedered the key target of PORT. 
PO-0705 Clinical outcomes for inoperable HCC treated with SBRT: results on 71 patients and 102 lesions. T. Comito

Material and Methods:
Patients with 1-3 inoperable HCC lesions with diameter ≤6cm were treated by SBRT. Prescription dose was 36-75Gy in 3-6 fractions. SBRT was delivered using the volumetric modulated arc therapy technique with flattening filter free photon beams. The primary end points of this study were in-field local control (LC) and toxicity. Secondary end points were overall survival (OS) and progression free survival (PFS).
Results: From February 2011 and April 2015, 71 patients with 102 HCC lesions were irradiated. All patients had Child-Turcotte-Pugh class A or B disease. Median follow-up was 9 months (range 5-43 months). Actuarial LC at 1 and 2-years was 92% and 81%. An Equivalent Dose >100Gy was a significant prognostic factor for LC in univariate analysis, with a 1-2 years LC rates of 99%-94% for a subgroup of lesions treated with a BED ≥100Gy and 58% -29% for lesions treated with a BED <100Gy (p<0.001). Median OS was 25 months. Actuarial OS at 1 and 2 years was 70% and 60%, respectively. Univariate analysis showed that OS is correlated with LC (p<0.02), BED>100 (p<0.05) and Cumulative GTV<5cm (p<0.04). Median PFS was 9 months. Grade ≥3 toxicity was observed in 7 patients (18%). No classic RILD was observed.
Conclusion:
Our study shows that SBRT is a safe and effective treatment for selected patients with inoperable HCC. Local control rates and toxicity profile were encouraging.
PO-0706 Supraclavicular lymphnode disease is not an independent prognostic factor in esophageal cancer P. Jeene
Purpose or Objective: In the TNM 7 staging, supraclavicular lymph nodes (SCN) are considered distant metastasis and thus prognostically unfavourable. This is one of the reasons for a generally accepted policy to treat these patients with supraclavicular disease spread and without further distant metastases with definitive chemoradiation (dCRT), irrespective of N stage. However, the worse prognostic value of a supraclavicular disease may be questioned. We analysed the prognostic value of supraclavicular disease in dCRT for esophageal cancer.
Material and Methods:
We retrospectively analyzed 207 patients treated between 2003 and 2013 with a standardized protocol of definitive chemoradiation (dCRT) for esophageal cancer to identify the prognostic value of metastasis in the supraclavicular lymphnodes on treatment failure and survival, with special attention to the relation between supraclavicular disease and N stage. All patients were treated with external beam radiotherapy (50.4 Gy in 28 fractions) combined with weekly concurrent paclitaxel 50 mg/m2and carboplatin AUC2.
Results: Median follow up time for patients alive was 43.3 months The median overall survival (OS) for all patients was 17.5 months. OS at 1, 3 and 5 year was 67%, 36.1% and 21.3% respectively. For patients with a metastasis in a supraclavicular lymph node, overall survival was 23.6 months compared to 17.1 months for patients without a metastasis in the SCN (p=0.51). In multivariate analyses , higher cT status, cNstatus and tumor length were found prognostically unfavorable, but a positive supraclavicular lymph node was not of independent prognostic value for survival (p= 0.67). The relationship between SCN involvement and N stage was analyzed separately. Median OS for tumors with SCN involvement and N0/1 disease was 49.0 months (15.4-82.6) compared to 17.4 months in patients with N2/3 disease (95%CI 99-24.8 p= 0.097). Median diseasefree survival (DFS) for tumors with SCN involvement and N0/1 disease was 51.6 months (95%CI 0-108.5) compared to 8.2 months in the N2/3 group (95%CI 6.2-10.1 p= 0.028). No significant difference in
